Nothing Special   »   [go: up one dir, main page]

SI1317559T1 - Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna - Google Patents

Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna

Info

Publication number
SI1317559T1
SI1317559T1 SI200130900T SI200130900T SI1317559T1 SI 1317559 T1 SI1317559 T1 SI 1317559T1 SI 200130900 T SI200130900 T SI 200130900T SI 200130900 T SI200130900 T SI 200130900T SI 1317559 T1 SI1317559 T1 SI 1317559T1
Authority
SI
Slovenia
Prior art keywords
rna
attenuated
viruses
present
virus
Prior art date
Application number
SI200130900T
Other languages
English (en)
Inventor
Erich Hoffmann
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of SI1317559T1 publication Critical patent/SI1317559T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00061—Methods of inactivation or attenuation
    • C12N2720/00063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200130900T 2000-04-28 2001-04-27 Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna SI1317559T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20067900P 2000-04-28 2000-04-28
PCT/US2001/013656 WO2001083794A2 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus
EP01932704A EP1317559B1 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious negative strand rna virus

Publications (1)

Publication Number Publication Date
SI1317559T1 true SI1317559T1 (sl) 2009-04-30

Family

ID=22742710

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130900T SI1317559T1 (sl) 2000-04-28 2001-04-27 Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna

Country Status (26)

Country Link
US (6) US6951754B2 (sl)
EP (2) EP2085468A1 (sl)
JP (3) JP2004500842A (sl)
KR (2) KR100862758B1 (sl)
CN (2) CN101580849B (sl)
AT (1) ATE420189T1 (sl)
AU (3) AU2001259211B2 (sl)
BR (1) BRPI0110607B8 (sl)
CA (1) CA2406100C (sl)
CY (1) CY1108735T1 (sl)
DE (2) DE122011100039I1 (sl)
DK (1) DK1317559T3 (sl)
EA (1) EA006311B1 (sl)
ES (1) ES2319864T3 (sl)
HK (1) HK1055992A1 (sl)
HU (1) HU229101B1 (sl)
IL (1) IL152426A (sl)
MX (1) MXPA02010642A (sl)
NO (1) NO332080B1 (sl)
NZ (1) NZ521840A (sl)
PL (1) PL205955B1 (sl)
PT (1) PT1317559E (sl)
SI (1) SI1317559T1 (sl)
UA (1) UA84254C2 (sl)
WO (1) WO2001083794A2 (sl)
ZA (1) ZA200208065B (sl)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU2001259211B2 (en) * 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
AU2003231083A1 (en) * 2002-04-26 2003-11-10 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.
EP1375670B1 (en) * 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
DE10248301A1 (de) * 2002-10-16 2004-04-29 Philipps-Universität Marburg Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CN101804202B (zh) 2003-02-25 2014-06-18 米迪缪尼有限公司 制备流感疫苗组合物的方法
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
MX342639B (es) * 2003-05-28 2016-10-07 Wisconsin Alumni Res Found Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
JP2006525815A (ja) * 2003-05-28 2006-11-16 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション Ｐｏｌｉｉプロモーターおよびリボザイムを有する組換えインフルエンザベクター
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
DE102004013335A1 (de) * 2004-03-17 2005-10-13 TransMIT Gesellschaft für Technologietransfer mbH Impfstoff gegen Influenza basierend auf Geflügelpestviren
CA2567446C (en) * 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
DK1748790T3 (en) 2004-05-24 2015-10-19 Medimmune Llc Multiplasmidsystem for the production of influenza
EP2465927B1 (en) * 2004-05-25 2014-12-24 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
JP5147405B2 (ja) 2004-10-06 2013-02-20 メディミューン，エルエルシー 冷蔵温度安定型インフルエンザワクチン組成物
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
CN101128598B (zh) * 2004-12-08 2013-04-24 米迪缪尼有限公司 生产流感疫苗组合物的方法
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
US7959930B2 (en) * 2004-12-24 2011-06-14 Abbott Biologicals B.V. Rescue of influenza virus
EP2471552B1 (en) * 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
JP2008546408A (ja) 2005-06-21 2008-12-25 メッドイミューン バクシーンズ，インコーポレイティド 異種プロテアーゼを発現させるための方法および組成物
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP1945778B1 (en) 2005-10-17 2012-12-26 MedImmune, LLC Methods of increasing influenza virus replication
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
DE202006021242U1 (de) 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
AU2006310336B2 (en) 2005-11-04 2011-02-03 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
DK1951299T3 (da) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
US20090047353A1 (en) * 2005-11-04 2009-02-19 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
AU2014202470B2 (en) * 2006-03-31 2016-08-04 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
JP2009532352A (ja) * 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
AU2012204138B2 (en) * 2006-03-31 2014-02-06 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
KR101436176B1 (ko) 2006-04-19 2014-09-02 메디뮨 엘엘씨 개의 세포 내에서 네거티브-센스 바이러스 ｒｎａ를 발현시키기 위한 방법 및 조성물
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101586971B1 (ko) 2006-08-09 2016-02-22 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN101627113B (zh) 2006-09-15 2013-04-24 米迪缪尼有限公司 支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
WO2008080091A2 (en) * 2006-12-21 2008-07-03 Vical Incorporated Activation of rig-i pathway
WO2008153236A1 (en) * 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
WO2008157583A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
BRPI0820328B8 (pt) 2007-10-02 2021-07-27 Labrador Diagnostics Llc sistema e método para detecção automática de uma pluralidade de analitos em uma amostra de fluido corporal
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101970645B (zh) * 2007-11-26 2018-11-30 伦敦卫生及热带医学学院 呼肠弧病毒家族病毒的疫苗病毒株的制造方法
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
EP2318043A4 (en) * 2008-07-11 2012-01-25 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2233568A1 (en) * 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
RU2535970C2 (ru) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
KR20120039047A (ko) 2009-07-31 2012-04-24 노파르티스 아게 역유전학 시스템
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CA2778332A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
CN102051345B (zh) * 2009-11-09 2013-04-17 中国医学科学院医药生物技术研究所 一种抗流行性感冒病毒药物的筛选方法
AU2011217903B2 (en) * 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN103237890A (zh) 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 用于产生rna 病毒的方法和辅助病毒
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR085087A1 (es) 2011-01-21 2013-09-11 Theranos Inc Sistemas y metodos para maximizar el uso de muestras
WO2012108195A1 (ja) * 2011-02-08 2012-08-16 国立大学法人三重大学 遺伝子導入用ウイルスベクターの製造方法
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
WO2013130132A1 (en) 2011-10-07 2013-09-06 Medimmune, Llc Influenza hemagglutinin variants
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
JP6335167B2 (ja) 2012-08-03 2018-05-30 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ 感染性インフルエンザウイルスの産生
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CN105263516A (zh) 2012-12-18 2016-01-20 西奈山伊坎医学院 流感病毒疫苗及其用途
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
AU2014363991B2 (en) 2013-12-09 2020-08-27 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
CN103757032B (zh) * 2014-01-28 2017-06-06 中国人民解放军第三0二医院 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
MA40773A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
JP6624736B2 (ja) * 2015-11-18 2019-12-25 国立研究開発法人農業・食品産業技術総合研究機構 インフルエンザウイルス解析装置、インフルエンザウイルス解析方法及びインフルエンザウイルス解析プログラム
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
MA45165A (fr) 2016-06-02 2019-04-10 Sanofi Pasteur Inc Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
US10548967B2 (en) 2016-11-30 2020-02-04 Boehringer Ingelheim Animal Health USA Inc. Attenuated swine influenza vaccines and methods of making and use thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
KR102614346B1 (ko) 2020-12-14 2023-12-14 서울대학교산학협력단 Ｈ5ｎ6 재조합 인플루엔자 바이러스, 이의 제조용 조성물, 및 이를 포함하는 백신 조성물
WO2024194651A1 (en) 2023-03-22 2024-09-26 Lentitek Ltd Expression construct

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
NZ296861A (en) 1994-11-16 1998-05-27 St Jude Childrens Res Hospital Replicating human influenza virus in a vero cell culture involving maintaining consistent minimum concentration of trypsin in the culture medium
BRPI0009580B8 (pt) 1999-04-06 2021-05-25 Wisconsin Alumni Res Found processo para preparar vírus influenza infecciosos na ausência de um vírus auxiliar, preparação de vírus influenza infeccioso recombinante, e, composição.
AU2001259211B2 (en) * 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
AU2003231083A1 (en) 2002-04-26 2003-11-10 Medimmune, Llc Multi plasmid system for the production of influenza virus
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus

Also Published As

Publication number Publication date
HK1055992A1 (en) 2004-01-30
CN1856575A (zh) 2006-11-01
DE60137345D1 (de) 2009-02-26
CY1108735T1 (el) 2014-04-09
AU2001259211B2 (en) 2006-07-13
US20080233560A1 (en) 2008-09-25
KR20030072209A (ko) 2003-09-13
AU2006228054A1 (en) 2006-11-02
CN101580849A (zh) 2009-11-18
US8309099B2 (en) 2012-11-13
EP1317559B1 (en) 2009-01-07
US20050186563A1 (en) 2005-08-25
US20080311148A1 (en) 2008-12-18
AU2006228054B2 (en) 2010-04-29
IL152426A (en) 2011-07-31
MXPA02010642A (es) 2004-05-17
NO332080B1 (no) 2012-06-18
EA200201164A1 (ru) 2003-10-30
KR100862758B1 (ko) 2008-10-13
EP2085468A1 (en) 2009-08-05
CN101580849B (zh) 2012-11-21
ATE420189T1 (de) 2009-01-15
CA2406100C (en) 2010-11-02
JP5837891B2 (ja) 2015-12-24
US20080311149A1 (en) 2008-12-18
EA006311B1 (ru) 2005-10-27
PL205955B1 (pl) 2010-06-30
IL152426A0 (en) 2003-05-29
DK1317559T3 (da) 2009-03-23
JP2013116112A (ja) 2013-06-13
US6951754B2 (en) 2005-10-04
NZ521840A (en) 2004-11-26
EP1317559A2 (en) 2003-06-11
PL366064A1 (en) 2005-01-24
HU229101B1 (en) 2013-07-29
JP2010042030A (ja) 2010-02-25
CA2406100A1 (en) 2001-11-08
KR20070086094A (ko) 2007-08-27
US7972843B2 (en) 2011-07-05
PT1317559E (pt) 2009-02-12
HUP0303036A2 (hu) 2003-12-29
CN100489107C (zh) 2009-05-20
BRPI0110607B8 (pt) 2021-05-25
UA84254C2 (ru) 2008-10-10
HUP0303036A3 (en) 2004-10-28
WO2001083794A2 (en) 2001-11-08
US7312064B2 (en) 2007-12-25
WO2001083794A3 (en) 2003-03-27
KR100848719B1 (ko) 2008-07-25
BRPI0110607B1 (pt) 2020-08-11
BR0110607A (pt) 2004-06-22
DE122011100039I1 (de) 2011-12-08
US20020164770A1 (en) 2002-11-07
JP5745758B2 (ja) 2015-07-08
JP2004500842A (ja) 2004-01-15
NO20025171L (no) 2002-12-30
NO20025171D0 (no) 2002-10-28
ZA200208065B (en) 2003-11-12
AU5921101A (en) 2001-11-12
US20110250232A1 (en) 2011-10-13
ES2319864T3 (es) 2009-05-14

Similar Documents

Publication Publication Date Title
HK1055992A1 (en) Dna transfection system for the generation of infectious negative strand rna virus
EP1270016A4 (en) VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
Lauer et al. Multivalent and multipathogen viral vector vaccines
Kobinger et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
Rodrigues et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology
Pinto et al. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers
Pandey et al. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine
Ma et al. Swine influenza vaccines: current status and future perspectives
NZ514132A (en) Stable recombinant influenza viruses free of helper viruses
JP2004500842A5 (sl)
Ding et al. Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
Palese et al. Development of novel influenza virus vaccines and vectors
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
EP1427443A4 (en) VACCINE USING VIRUS VIRUS-ADJUSTED PAPILLOMA VIRUS PROTEINS
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
Xiao et al. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice
WO1999057284A3 (en) Attenuated influenza viruses
Smith et al. Vaccinia virus recombinants expressing genes from pathogenic agents have potential as live vaccines.
Dulin et al. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2
Mazurkova et al. Comparative analysis of reproduction of influenza virus strains in cell lines perspective for the creation of cultural vaccines grown on nutrient medium on the basis of rise flour protein hydrolysate
Park Immunogenicity of replication-defective recombinant vesicular stomatitis virus expressing Middle East respiratory syndrome coronavirus spike protein in mice
Ghendon et al. Molecular-genetic analysis of the cold-adapted strain, a donor of attenuation for live influenza vaccine for children, of the recombinants produced on its basis, and of isolates from vaccinated children.
Pandey et al. Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection
WO2002089728A3 (en) Recombinant rhabdoviruses as live-viral vaccines